Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians

DOI10.1002/BIMJ.200610250zbMATH Open1442.62371OpenAlexW2036748314WikidataQ80261875 ScholiaQ80261875MaRDI QIDQ5122844FDOQ5122844

Authors: Paul P. Gallo, Willi Maurer 

Publication date: 24 September 2020

Published in: Biometrical Journal (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1002/bimj.200610250

Recommendations

• Adaptive designs from the viewpoint of an academic biostatistician
• Methodological developments vs. regulatory requirements
• Opening the adaptive toolbox
• A consultant's perspective on the regulatory hurdles to adaptive trials
• Rejoinder

zbMATH Keywords

experimental designmissing datanon-inferiorityadaptive designsbiostatisticsnon-inferiority trialsmultiple endpointssuperiorityphase III clinical trialsclinical trial simulationadaptive information designadaptive study designsdropping a treatment armFDA critical pathguidance developmentquantitative risk/safety assessmentregulatory evaluation

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cited In (8)

• A Regulatory View on Adaptive/Flexible Clinical Trial Design
• Rejoinder
• FDA's critical path initiative: a perspective on contributions of biostatistics
• Adaptive designs from the viewpoint of an academic biostatistician
• A consultant's perspective on the regulatory hurdles to adaptive trials
• Opening the adaptive toolbox
• Methodological developments vs. regulatory requirements
• Rejoinder to Discussions on “Approval policies for modifications to machine learning‐based software as a medical device: A study of bio‐creep”

This page was built for publication: Challenges in implementing adaptive designs: comments on the viewpoints expressed by regulatory statisticians

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5122844)